



Ref: Syn/CS/SE/PR/2023-24/Oct/07

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

October 17, 2023

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Press Release in respect of results for the quarter and half year ended September 30, 2023.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled “**Syngene reports strong second quarter results: Revenue from operations up 18.5% to Rs 910 crores, PAT (before exceptional items) up 20% to Rs 122 crores**”

The above-mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

Enclosed: Press Release along with fact sheet

Press Release

**Syngene reports strong second quarter results:
Revenue from operations up 18.5% to Rs 910 crores,
PAT (before exceptional items) up 20% to Rs 122 crores**

First half FY24 revenue from operations was up 22% to Rs 1,718 crores;

Profit after tax (before exceptional items) up 23% to Rs 215 crores

Bangalore, October 17, 2023: Syngene International Limited today announced its second quarter and half year financial results. Reported revenue from operations for the quarter was up 18.5% year-on-year to Rs. 910 crores, around 15% at constant currency. Profit after tax (before exceptional items) for the quarter increased 20% year-on-year to Rs 122 crores.

For the half year ended 30th September 2023, reported revenue from operations was up 22%, around 17% at constant currency, and profit after tax (before exceptional items) increased by 23% to Rs 215 crores compared to the same period last year.

Commenting on the quarter, **Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited**, said, *“I am pleased to report a strong set of results for the second quarter and first half of the financial year, particularly in our Development and Manufacturing Services. In Development Services, we also added a new non-GMP capability center to meet market demand for agile, cost-efficient, early phase development and scale-up services. In Manufacturing, we made good progress on our long-term biologics partnership with Zoetis, as well as commissioning a state of the art, digitally-enabled Quality Control laboratory to support our growing biologics operations. The acquisition of a multi-modal facility from Stelis Biopharma Ltd, announced last quarter, is progressing.*

Within research services, our Dedicated Centers made a steady contribution to growth and in Discovery Services, while global demand remained generally healthy, we saw the US-based biotech segment showing signs of slowed growth year-on-year as companies adjust to a new funding environment.

Long term sector fundamentals remain strong and we expect continued growth but at a lower level in the second half of the year, this short-term slowing in the US biotech segment is reflected in our latest outlook.

Overall, we reported a strong first half to the year and I am pleased with the good progress made on our strategic priorities in both our research services and our development and manufacturing divisions.”

Sibaji Biswas, Chief Financial Officer, Syngene International Limited added, *“We have reported strong second quarter and half year results with operating EBIT growth, tracking revenue growth.*

During the second half of the year, we will continue to invest in new science, technology and digitization, as well as building capacity to support future growth, while balancing discretionary expenditure in order to maintain margins.”

Q2 FY24 Financial Highlights (All numbers are in Indian rupees in Crores except margins)

	Q2 FY23	Q2 FY24	YoY Change (%)
Revenue from operations	768	910	18.5%
Reported Revenue	784	932	19%
Reported EBITDA	232	276	19%
<i>Reported EBITDA margin (%)</i>	<i>29.6%</i>	<i>29.6%</i>	
PAT before exceptional item	102	122	20%
<i>PAT Margin (%) (before exceptional items)</i>	<i>13.0%</i>	<i>13.1%</i>	
PAT after exceptional item*	102	117	14%

**Note: Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of the multi-modal facility of Stelis Biopharma Limited.*

H1 FY24 Financial Highlights (All numbers are in Indian rupees in Crores except margins)

	H1 FY23	H1 FY24	YoY Change (%)
Revenue from operations	1,413	1,718	22%
Reported Revenue	1,443	1,763	22%
Reported EBITDA	420	511	22%

Reported EBITDA margin (%)	29.1%	29.0%	
PAT before exceptional item	176	215	23%
PAT Margin (%)	12.2%	12.2%	
PAT after exceptional item*	176	210	19%

**Note: Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of the multi-modal facility of Stelis Biopharma Limited.*

Business updates

The second quarter was underpinned by strong performances in Development and Manufacturing Services supported by sustained momentum in the Dedicated Centers.

In Manufacturing Services, the Company continued to make good progress on the long-term biologics manufacturing partnership with Zoetis. During the quarter, the Company commissioned a Quality Control laboratory for biologics testing equipped with the latest technology to drive higher throughput and seamless data transfer.

In the first quarter, Syngene announced the intention to acquire a multi-modal facility from Stelis Biopharma Ltd and the transaction is progressing.

During the quarter, the Company operationalized a non-GMP facility, which added the capability to conduct API synthesis in a non-GMP environment resulting in agile, cost-effective solutions for early phase development projects.

First half performance was characterised by positive contributions from all divisions, as well as the achievement of several significant strategic goals: the agreement to acquire the multi-modal biologics facility from Stelis Biopharma Ltd; the purchase of a 17-acre land parcel in Genome Valley, Hyderabad, as an extension to the existing research campus; and the regulatory approval from the US Food and Drug Administration (US FDA) for the commercial manufacturing facility in Mangalore.

Guidance

While the Company delivered strong performance in the first half, with the temporary slowdown in US biotech funding, we expect continued growth at a lower level in the second half of the year. Adjusting for this, against our previous guidance of high teens constant

currency growth, we now expect the revenue to grow at mid-teens on constant currency basis.

Earnings call

Syngene will host an investor call at 3.00 pm IST on October 18, 2023, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1279/ +91 22 7115 8180. Other toll numbers are listed in the conference call invitation which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available on the website and until 25th October 2023, on +91 22 71945757, Playback ID: 61353. We will aim to post the transcript of the conference call on the Company website within seven working days of the investor conference call.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG) report, visit <https://esgreport.syngeneintl.com/>.

Contact details

Investor Contact	Media Contact
Krishnan G / Suruchi Daga P: +91 80 6891 9807 M: +919819992927 / 8800176009 Fax: +91 80 2852 3423 E: krishnan.g@syngeneintl.com E: suruchi.daga@syngeneintl.com	Shotorupa Ghosh / Vijay Jeevanandham M: +91 8450977080/ +917760759922 Fax: +91 80 2852 3423 E: Shotorupa.ghosh@syngeneintl.com E: Vijay.jeevanandham@syngeneintl.com

Disclaimer: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.*

SYNGENE GROUP

FACT SHEET

**Financial results for the quarter ended 30 Sep 2023
(Consolidated)**



SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)

BALANCE SHEET

(Rs. Millions)

	30 Sep 2023	31 March 2023
ASSETS		
Non-current assets		
Property, plant and equipment	23,706	23,834
Capital work-in-progress	2,360	1,769
Right-of-use assets	3,110	2,169
Investment property	445	481
Other intangible assets	203	185
Intangible assets under development	46	
Financial assets		
(i) Investments	478	941
(ii) Derivative assets	1,430	841
(iii) Other financial assets	804	1,511
Deferred tax assets (net)	480	696
Income tax assets (net)	1,497	1,381
Other non-current assets	154	249
Total non-current assets	34,713	34,057
Current assets		
Inventories	3,204	3,328
Financial assets		
(i) Investments	4,925	8,244
(ii) Trade receivables	4,188	5,293
(iii) Cash and cash equivalents	1,683	895
(iv) Bank balances other than (iii) above	7,498	4,422
(v) Derivative assets	346	460
(vi) Other financial assets	980	552
Other current assets	925	1,059
Total current assets	23,749	24,253
Total assets	58,462	58,310
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,020	4,014
Other equity	34,889	32,166
Total equity	38,909	36,180
LIABILITIES		
Non - current liabilities		
Financial liabilities		
(i) Borrowings	1,414	4,890
(i)(a) Lease liabilities	2,755	2,142
(ii) Derivative liabilities	33	215
Provisions	364	437
Other non-current liabilities	2,728	2,564
Total non-current liabilities	7,294	10,248
Current liabilities		
Financial liabilities		
(i) Borrowings	3,785	863
(i)(a) Lease liabilities	376	257
(ii) Trade payables	2,796	2,580
(iii) Derivative liabilities	258	377
(iv) Other financial liabilities	725	582
Provisions	735	510
Current tax liabilities (net)	197	147
Other current liabilities	3,387	6,566
Total current liabilities	12,259	11,882
Total equity and liabilities	58,462	58,310

(Rs. Millions)

KEY FINANCIAL INFORMATION

		FY23	FY24	Movement
		Q2	Q2	%
Revenue from operations	<i>Rs. Mn</i>	7,681	9,101	18.5
EBITDA from operations	<i>Rs. Mn</i>	2,165	2,540	17.4
EBITDA from operations margin	%*	28.2	27.9	-27bps
EBIT from operations	<i>Rs. Mn</i>	1,262	1,494	18.4
EBIT from operations margin	%*	16.4	16.4	-1bps
PAT before exceptional item	<i>Rs. Mn</i>	1,020	1,220	19.6
PAT margin	%	13.0	13.1	7bps

		F23	FY24	Movement
		Q2	Q2	%
Revenue from operations	<i>Rs. Mn</i>	7,681	9,101	18.5
Other income	<i>Rs. Mn</i>	154	216	40.1
Reported revenue	<i>Rs. Mn</i>	7,835	9,317	18.9
Material costs	<i>Rs. Mn</i>	(1,990)	(2,672)	34.3
	%*	(25.9)	(29.4)	-345bps
Staff costs	<i>Rs. Mn</i>	(2,185)	(2,412)	10.4
	%*	(28.4)	(26.5)	194bps
Other direct costs#	<i>Rs. Mn</i>	(288)	(275)	(4.4)
	%*	(3.7)	(3.0)	73bps
Other expenses	<i>Rs. Mn</i>	(868)	(1,022)	17.7
	%*	(11.3)	(11.2)	7bps
Foreign exchange fluctuation gain/(loss), net	<i>Rs. Mn</i>	(186)	(179)	(4.0)
EBITDA	<i>Rs. Mn</i>	2,319	2,757	18.9
Depreciation and amortisation expenses	<i>Rs. Mn</i>	(902)	(1,046)	15.9
EBIT	<i>Rs. Mn</i>	1,417	1,711	20.8
Finance costs	<i>Rs. Mn</i>	(117)	(130)	10.7
PBT	<i>Rs. Mn</i>	1,300	1,581	21.7
Tax	<i>Rs. Mn</i>	(280)	(361)	28.9
PAT before exceptional item	<i>Rs. Mn</i>	1,020	1,220	19.6
Exceptional item	<i>Rs. Mn</i>	-	(53)	N/a
PAT after exceptional item	<i>Rs. Mn</i>	1,020	1,167	14.4

includes power, utility and clinical trial cost

* % over revenue from operations

Note: Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL)

(Rs. Millions)

KEY FINANCIAL INFORMATION

		FY23	FY24	Movement
		H1	H1	%
Revenue from operations	<i>Rs. Mn</i>	14,125	17,182	21.6
EBITDA from operations	<i>Rs. Mn</i>	3,892	4,660	19.7
EBITDA from operations margin	%*	27.6	27.1	-44bps
EBIT from operations	<i>Rs. Mn</i>	2,129	2,593	21.8
EBIT from operations margin	%*	15.1	15.1	2bps
PAT before exceptional item	<i>Rs. Mn</i>	1,759	2,154	22.5
PAT margin	%	12.2	12.2	3bps

		FY23	FY24	Movement
		H1	H1	%
Revenue from operations	<i>Rs. Mn</i>	14,125	17,182	21.6
Other income	<i>Rs. Mn</i>	309	452	46.2
Reported revenue	<i>Rs. Mn</i>	14,435	17,634	22.2
Material costs	<i>Rs. Mn</i>	(3,602)	(4,900)	36.0
	%*	(25.5)	(28.5)	-302bps
Staff costs	<i>Rs. Mn</i>	(4,155)	(4,701)	13.1
	%*	(29.4)	(27.4)	206bps
Other direct costs#	<i>Rs. Mn</i>	(571)	(551)	(3.6)
	%*	(8.1)	(6.4)	171bps
Other expenses	<i>Rs. Mn</i>	(1,685)	(2,036)	20.8
	%*	(11.9)	(11.8)	8bps
Foreign exchange fluctuation gain/(loss), net	<i>Rs. Mn</i>	(220)	(334)	51.6
EBITDA	<i>Rs. Mn</i>	4,202	5,112	21.7
Depreciation and amortisation expenses	<i>Rs. Mn</i>	(1,764)	(2,067)	17.2
EBIT	<i>Rs. Mn</i>	2,438	3,045	24.9
Finance costs	<i>Rs. Mn</i>	(211)	(235)	11.4
PBT	<i>Rs. Mn</i>	2,227	2,810	26.2
Tax	<i>Rs. Mn</i>	(469)	(656)	40.0
PAT before exceptional item	<i>Rs. Mn</i>	1,759	2,154	22.5
Exceptional item	<i>Rs. Mn</i>	-	(53)	N/a
PAT after exceptional item	<i>Rs. Mn</i>	1,759	2,101	19.4

includes power, utility and clinical trial cost

* % over revenue from operations

Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL)

(Rs. Millions)

KEY FINANCIAL INFORMATION							
		FY23	FY23	FY23	FY23	FY24	FY24
		Q1	Q2	Q3	Q4	Q1	Q2
Revenue from operations	<i>Rs. Mn</i>	6,445	7,681	7,859	9,944	8,081	9,101
EBITDA from operations	<i>Rs. Mn</i>	1,728	2,165	2,310	3,140	2,119	2,540
EBITDA from operations margin	%*	26.8	28.2	29.4	31.6	26.2	27.9
EBIT from operations	<i>Rs. Mn</i>	866	1,262	1,363	2,185	1,098	1,494
EBIT from operations margin	%*	13.4	16.4	17.3	22.0	13.6	16.4
PAT before exceptional item	<i>Rs. Mn</i>	739	1,020	1,097	1,787	934	1,220
PAT margin	%	11.2	13.0	13.7	17.6	11.2	13.1
		FY23	FY23	FY23	FY23	FY24	FY24
		Q1	Q2	Q3	Q4	Q1	Q2
Revenue from operations	<i>Rs. Mn</i>	6,445	7,681	7,859	9,944	8,081	9,101
Other income	<i>Rs. Mn</i>	155	154	172	228	236	216
Reported revenue	<i>Rs. Mn</i>	6,600	7,835	8,031	10,172	8,317	9,317
Material costs	<i>Rs. Mn</i>	(1,612)	(1,990)	(2,061)	(2,938)	(2,228)	(2,672)
	%*	(25.0)	(25.9)	(26.2)	(29.5)	(27.6)	(29.4)
Staff costs	<i>Rs. Mn</i>	(1,971)	(2,185)	(2,192)	(2,528)	(2,288)	(2,412)
	%*	(30.6)	(28.4)	(27.9)	(25.4)	(28.3)	(26.5)
Other direct costs#	<i>Rs. Mn</i>	(283)	(288)	(264)	(273)	(275)	(275)
	%*	(4.4)	(3.7)	(3.4)	(2.7)	(3.4)	(3.0)
Other expenses	<i>Rs. Mn</i>	(817)	(867)	(876)	(1,022)	(1,016)	(1,022)
	%*	(12.7)	(11.3)	(11.1)	(10.3)	(12.6)	(11.2)
Foreign exchange fluctuation gain/(loss), net	<i>Rs. Mn</i>	(34)	(186)	(156)	(42)	(155)	(179)
EBITDA	<i>Rs. Mn</i>	1,883	2,319	2,482	3,369	2,355	2,757
Depreciation and amortisation expenses	<i>Rs. Mn</i>	(861)	(902)	(946)	(956)	(1,021)	(1,046)
EBIT	<i>Rs. Mn</i>	1,022	1,417	1,536	2,413	1,334	1,711
Finance costs	<i>Rs. Mn</i>	(94)	(117)	(137)	(104)	(105)	(130)
PBT	<i>Rs. Mn</i>	928	1,300	1,399	2,309	1,229	1,581
Tax	<i>Rs. Mn</i>	(189)	(280)	(302)	(522)	(295)	(361)
PAT before exceptional item	<i>Rs. Mn</i>	739	1,020	1,097	1,787	934	1,220
Exceptional item (refer note)	<i>Rs. Mn</i>	-	-	-	-	-	(53)
PAT after exceptional item	<i>Rs. Mn</i>	739	1,020	1,097	1,787	934	1,167

includes power, utility and clinical trial cost

* % over revenue from operations

Note:

Exceptional item relating to FY22 pertains to an exceptional downward adjustment of Rs. 253 million (net of tax) on account of the Government's decision during that quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs. 50 million for the Financial Year 2020.

Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL)